$MNPR
Monopar Therapeutics Inc

2024 Q1 Form 10-K Financial Statement

#000143774924009687 Filed on March 28, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $757.3K $876.4K $3.231M
YoY Change -13.12% 8.37% 9.7%
% of Gross Profit
Research & Development $966.1K $1.036M $5.600M
YoY Change -41.57% -50.76% -26.23%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.723M $1.912M $8.831M
YoY Change -31.75% -34.27% -16.19%
Operating Profit -$1.723M -$8.831M
YoY Change -31.75% -16.19%
Interest Expense $82.17K $98.07K $429.0K
YoY Change -9.19% 674.64% 1919.96%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.641M -$1.814M -$8.402M
YoY Change -32.59% -37.37% -20.1%
Income Tax $800.00
% Of Pretax Income
Net Earnings -$1.641M -$1.814M -$8.402M
YoY Change -32.6% -37.37% -20.1%
Net Earnings / Revenue
Basic Earnings Per Share -$0.10 -$0.61
Diluted Earnings Per Share -$0.10 -$0.12 -$0.61
COMMON SHARES
Basic Shares Outstanding 17.45M 14.87M 13.82M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.03M $13.81M $7.266M
YoY Change 37.25% 5.27% -44.62%
Cash & Equivalents $7.808M $7.266M $7.266M
Short-Term Investments $8.219M $6.545M $0.00
Other Short-Term Assets $119.0K $66.43K $66.43K
YoY Change 11.39% 44.48% 44.48%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $8.912M $7.333M $7.333M
YoY Change -24.36% -44.31% -44.31%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $12.65K $12.65K
YoY Change -100.0% -79.34% -79.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $12.65K $12.65K
YoY Change -100.0% -79.35% -79.34%
TOTAL ASSETS
Total Short-Term Assets $8.912M $7.333M $7.333M
Total Long-Term Assets $0.00 $12.65K $12.65K
Total Assets $8.912M $7.345M $7.345M
YoY Change -24.68% -44.47% -44.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.435M $1.749M $1.749M
YoY Change -50.3% -43.22% -43.22%
Accrued Expenses $8.410K $8.410K
YoY Change -82.69% -82.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.435M $1.757M $1.757M
YoY Change -50.3% -43.83% -43.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.435M $1.757M $1.757M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.435M $1.757M $1.757M
YoY Change -50.3% -43.98% -43.98%
SHAREHOLDERS EQUITY
Retained Earnings -$61.80M -$60.20M
YoY Change 13.94% 16.21%
Common Stock $69.32M $65.81M
YoY Change 524180.35% 508188.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.477M $5.588M $5.588M
YoY Change
Total Liabilities & Shareholders Equity $8.912M $7.345M $7.345M
YoY Change -24.68% -44.47% -44.47%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$1.641M -$1.814M -$8.402M
YoY Change -32.6% -37.37% -20.1%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.655M -$1.548M -$7.858M
YoY Change -27.11% 18.93% 8.71%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$983.3K $2.968M $4.928M
YoY Change -0.01% -160.34% -200.19%
Cash From Investing Activities -$983.3K $2.968M $4.928M
YoY Change -0.01% -160.34% -200.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.074M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $3.182M 337.2K $2.027M
YoY Change 295.36% 143.08% 6066.85%
NET CHANGE
Cash From Operating Activities -$1.655M -1.548M -$7.858M
Cash From Investing Activities -$983.3K 2.968M $4.928M
Cash From Financing Activities $3.182M 337.2K $2.027M
Net Change In Cash $541.5K 1.757M -$920.1K
YoY Change -122.01% -128.89% -92.41%
FREE CASH FLOW
Cash From Operating Activities -$1.655M -$1.548M -$7.858M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14904497
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14904497
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12946573
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12946573
CY2022 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
87611 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
98230 usd
us-gaap Revenues
Revenues
0 usd
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14904497
CY2023Q4 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P0Y2M12D
CY2022Q4 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P1Y2M12D
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-39070
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0463781
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
1000 Skokie Blvd., Suite 350
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Wilmette
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
IL
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
60091
CY2023 dei City Area Code
CityAreaCode
847
CY2023 dei Local Phone Number
LocalPhoneNumber
388-0349
CY2023 dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
CY2023 dei Trading Symbol
TradingSymbol
MNPR
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-51804021 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5587766 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10089652 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7345159 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13226954 usd
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
4608643 usd
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17454925
CY2023 dei Auditor Firm
AuditorFirmId
207
CY2023 dei Auditor Name
AuditorName
BPM LLP
CY2023 dei Auditor Location
AuditorLocation
Walnut Creek, California
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7266080 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8186194 usd
CY2023Q4 us-gaap Investments
Investments
0 usd
CY2022Q4 us-gaap Investments
Investments
4933550 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
66433 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
45982 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
7332513 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
13165726 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
12646 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
61228 usd
CY2023Q4 us-gaap Assets
Assets
7345159 usd
CY2022Q4 us-gaap Assets
Assets
13226954 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1757393 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3128894 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1757393 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3128894 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8408 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1757393 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3137302 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
14905 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
12947 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
65793210 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
61871784 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-14132 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
8942 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60206217 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5600193 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7591601 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3231042 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2945276 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
8831235 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
10536877 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-8831235 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-10536877 usd
CY2023 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
429039 usd
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
21239 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-8402196 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-10515638 usd
CY2023 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-17272 usd
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-2937 usd
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5802 usd
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
15039 usd
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8425270 usd
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10503536 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13823951
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12718166
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
18941071 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
87318 usd
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
169 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1641263 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-10515638 usd
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
12102 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10089652 usd
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2072504 usd
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1897849 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-8402196 usd
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-23074 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5587766 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-8402196 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-10515638 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
1897849 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1641263 usd
CY2023 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
20410 usd
CY2022 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-171755 usd
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1333536 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1478299 usd
CY2023 mnpr Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
-0 usd
CY2022 mnpr Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
4238 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7858293 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7228559 usd
CY2023 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
7882094 usd
CY2022 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
4918511 usd
CY2023 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
12809842 usd
CY2022 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
0 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4927748 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4918511 usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2074196 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
109337 usd
CY2023 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
46969 usd
CY2022 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
76633 usd
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
169 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2027227 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32873 usd
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-16796 usd
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-3478 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-920114 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12117675 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8186194 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20303869 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7266080 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8186194 usd
CY2023 mnpr Accrued Financing Fees
AccruedFinancingFees
1692 usd
CY2022 mnpr Accrued Financing Fees
AccruedFinancingFees
22018 usd
CY2023 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a href="#" id="notes" title="notes"></a>Note <em style="font: inherit;">1</em> - Nature of Business and Liquidity</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Nature of Business</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Monopar Therapeutics Inc. (“Monopar” or the ”Company”) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar currently has several compounds in development: <em style="font: inherit;">1</em>) MNPR-<em style="font: inherit;">101</em>-Zr, a clinical stage uPAR-targeted radiodiagnostic imaging agent; <em style="font: inherit;">2</em>) MNPR-<em style="font: inherit;">101</em>-RIT, a late preclinical stage radiotherapeutic for advanced cancers; <em style="font: inherit;">3</em>) camsirubicin (generic name for MNPR-<em style="font: inherit;">201,</em> GPX-<em style="font: inherit;">150;</em> <em style="font: inherit;">5</em>-imino-<em style="font: inherit;">13</em>-deoxydoxorubicin), a Phase <em style="font: inherit;">1b</em> clinical stage novel analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart; and <em style="font: inherit;">4</em>) an early stage camsirubicin analog, MNPR-<em style="font: inherit;">202,</em> for various cancers. On <em style="font: inherit;"> March 27, 2023, </em>the Company discontinued its Validive Phase <em style="font: inherit;">2b/3</em> VOICE trial based upon its Data Safety Monitoring Board’s determination that the trial did <em style="font: inherit;">not</em> meet the pre-defined threshold for efficacy of a 15% absolute difference in severe oral mucositis prevention between Validive and placebo. The Company continued to record clinical site close-out related expenses for Validive throughout <em style="font: inherit;">2023.</em> The Company is <em style="font: inherit;">not</em> anticipating incurring any license or royalty obligations or incurring any significant expenses beyond <em style="font: inherit;">2023</em> related to Validive.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Liquidity</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company has incurred an accumulated deficit of approximately $60.2 million as of <em style="font: inherit;"> December 31, 2023</em> and since inception has <span style="-sec-ix-hidden:c109540545">not</span> generated any revenue. To date, the Company has primarily funded its operations with the net proceeds from the Company’s initial public offering of its common stock on Nasdaq, sales of its common stock in the public market through at-the-market sales agreements, private placements of convertible preferred stock and of common stock and cash provided in the camsirubicin asset purchase transaction. Management estimates that currently available cash will provide sufficient funds to enable the Company to meet its obligations at least through <em style="font: inherit;"> June 30, 2025. </em>The Company’s ability to fund its future operations, including the continued clinical development of  its MNPR-<em style="font: inherit;">101</em> radiopharma program and camsirubicin, is dependent upon its ability to execute its business strategy, to obtain additional funding and/or to execute collaborative research agreements. There can be <em style="font: inherit;">no</em> certainty that future financing or collaborative research agreements will occur in the amounts required or at a time needed to maintain operations, if at all.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i><b>Risks and Uncertainties</b></i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt -9pt 0pt -1pt;">The termination of the Company’s Validive clinical trial at the end of <em style="font: inherit;"> March 2023 </em>resulted in a decrease in the Company’s stock price. The closing bid price of the Company’s stock fell below <em style="font: inherit;">$1.00</em> for more than <em style="font: inherit;">30</em> consecutive trading days, and on <em style="font: inherit;"> August 28, 2023, </em>the Company received a notice from Nasdaq stating that it is out of compliance with Nasdaq listing standards giving the Company <em style="font: inherit;">180</em> days to regain compliance. On <em style="font: inherit;"> February 27, 2024, </em>the Company was granted a <em style="font: inherit;">second</em> <em style="font: inherit;">180</em>-day period to regain compliance; there can be <em style="font: inherit;">no</em> assurance that the Company will regain compliance within Nasdaq’s extended time limits and requirements. If the Company does <em style="font: inherit;">not</em> regain compliance, the Company would face delisting and it <em style="font: inherit;"> may </em>have serious adverse consequences on the Company’s ability to raise funds, which <em style="font: inherit;"> may </em>cause Monopar to delay, restructure or otherwise reconsider its operations. If it is necessary to effect a reverse stock split to attempt to cure the bid price deficiency, the impacts on the Company's stock price are uncertain and could be adverse.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt -9pt 0pt -1pt;">Market variables over which the Company has <em style="font: inherit;">no</em> control, such as inflation of product costs, higher capital costs, labor rates and fuel, freight and energy costs, as well as geopolitical events could cause the Company to suffer significant increases in its operating and administrative expenses.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt -9pt 0pt -1pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt -9pt 0pt -1pt;">The Russia-Ukraine war, and resulting sanctions against Russia and Russian entities or allies, have increased fuel costs and <em style="font: inherit;"> may </em>cause shipping delays. In addition, the Israel-Hamas war has created additional uncertainties. The broader economic, trade and financial market consequences of these events are uncertain at this time, which <em style="font: inherit;"> may </em>increase the cost of supplies for the Company’s clinical materials, <em style="font: inherit;"> may </em>delay the manufacture of its clinical materials, <em style="font: inherit;"> may </em>increase costs of other goods and services, or make it more difficult or costly to raise additional financing, any of which could cause an adverse effect on the Company’s clinical and development program and on the Company’s financial condition.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt -9pt 0pt -1pt;">There remains uncertainties as to the long-term impacts of COVID-<em style="font: inherit;">19</em> or any potential resurgences thereof. The Company is unable to estimate COVID-<em style="font: inherit;">19’s</em> or any future pandemic disease's financial impact or duration in light of treatment options and potential surges of new cases from current or future COVID-<em style="font: inherit;">19</em> variants or a future pandemic or its potential impact on the Company’s current clinical trial and development programs, including COVID-<em style="font: inherit;">19’s</em> or a future pandemic's effect on drug candidate manufacturing, shipping, patient recruitment at clinical sites and regulatory agencies around the globe. </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p>
CY2023Q4 mnpr Percentage Of Absolute Difference In Severe Oral Mucositis Prevention
PercentageOfAbsoluteDifferenceInSevereOralMucositisPrevention
0.15 pure
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60200000 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2022Q4 mnpr Insurance Premiums Dues Subscription And Software Cost Paid In Advance
InsurancePremiumsDuesSubscriptionAndSoftwareCostPaidInAdvance
10000 usd
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Concentration of Credit Risk</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The Company maintains cash and cash equivalents at <em style="font: inherit;">two</em> reputable financial institutions. As of <em style="font: inherit;"> December 31, 2023</em>, the balance at <em style="font: inherit;">one</em> financial institution was in excess of the $250,000 Federal Deposit Insurance Corporation (“FDIC”) insurable limit. The Company has <em style="font: inherit;">not</em> experienced any losses on its deposits since inception and management believes the Company is <em style="font: inherit;">not</em> exposed to significant risks with respect to these financial institutions.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p>
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13823951
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12718166
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2527092
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1915600
CY2022 mnpr Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriod
168000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.001
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1642950
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.28
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
508902
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.14
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
6535673 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
9237 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
6544910 usd
CY2023 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
12167457 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
15039 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
12182496 usd
CY2022 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0 usd
CY2022 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14904497
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1543989
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.78
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
604064
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.83
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
337103
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.13
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
42851
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.93
CY2023 mnpr Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriod
-0
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2109001
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.01
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
601746
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.37
CY2023Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2109001
CY2023 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y5M23D
CY2023Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1507255
CY2023 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P5Y7M20D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
508902
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
604064
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
980455 usd
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
970451 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
131413 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.01
CY2023Q4 mnpr Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Outstanding Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice
4.27
CY2023Q4 mnpr Sharebased Compensation Arrangement By Sharebased Payment Award Options Expected To Vest Outstanding Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice
3.37
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2.8 usd
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2124000 usd
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3421000 usd
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 usd
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 usd
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
800 usd
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
800 usd
CY2023 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0 usd
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0 usd
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
800 usd
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
800 usd
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0603 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0639 pure
CY2023 mnpr Effective Income Tax Rate Reconciliation Tax Credits Percent
EffectiveIncomeTaxRateReconciliationTaxCreditsPercent
0.0312 pure
CY2022 mnpr Effective Income Tax Rate Reconciliation Tax Credits Percent
EffectiveIncomeTaxRateReconciliationTaxCreditsPercent
0.0557 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0281 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0245 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2533 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3258 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0202 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0206 pure
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0001 pure
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0001 pure
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.065 pure
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3871391 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3548494 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1322457 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1254678 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
800998 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
630113 usd
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
4417201 usd
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
3824482 usd
CY2023Q4 mnpr Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrues Liabilities And Allowances
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruesLiabilitiesAndAllowances
76403 usd
CY2022Q4 mnpr Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrues Liabilities And Allowances
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruesLiabilitiesAndAllowances
96478 usd
CY2023Q4 mnpr Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
2777414 usd
CY2022Q4 mnpr Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
1787350 usd
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
13265864 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11141595 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
13265864 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11141595 usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
321175 usd
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
103104 usd
CY2023 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
65389 usd
CY2022 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
150701 usd
CY2023 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
50742 usd
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
67370 usd
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
335822 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
321175 usd
CY2023Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
335822 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-8402000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-10516000 usd
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13824000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12718000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
CY2023Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
4238 usd
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
50856 usd
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
34424 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
8476 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8476 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
68 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
8408 usd
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.065 pure
CY2023Q4 mnpr Operating Lease Right Of Use Asset Noncurrent
OperatingLeaseRightOfUseAssetNoncurrent
12646 usd
CY2022Q4 mnpr Operating Lease Right Of Use Asset Noncurrent
OperatingLeaseRightOfUseAssetNoncurrent
61228 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
12646 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
61228 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8408 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
8408 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
56990 usd

Files In Submission

Name View Source Status
R10.htm Edgar Link pending
0001437749-24-009687-index-headers.html Edgar Link pending
0001437749-24-009687-index.html Edgar Link pending
0001437749-24-009687.txt Edgar Link pending
0001437749-24-009687-xbrl.zip Edgar Link pending
ex_568896.htm Edgar Link pending
ex_568897.htm Edgar Link pending
ex_568898.htm Edgar Link pending
ex_568899.htm Edgar Link pending
ex_568900.htm Edgar Link pending
ex_568901.htm Edgar Link pending
ex_638639.htm Edgar Link pending
ex_643663.htm Edgar Link pending
fig1.jpg Edgar Link pending
figure2.jpg Edgar Link pending
figure3lu177.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mnpr-20231231.xsd Edgar Link pending
mnpr20231231_10k.htm Edgar Link pending
mtlogo01.jpg Edgar Link pending
pipelinechartv3forupload.jpg Edgar Link pending
R1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mnpr-20231231_cal.xml Edgar Link unprocessable
mnpr-20231231_def.xml Edgar Link unprocessable
mnpr-20231231_lab.xml Edgar Link unprocessable
mnpr-20231231_pre.xml Edgar Link unprocessable
mnpr20231231_10k_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending